Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 12.68B |
| Revenue (ttm) | 3.35B |
| Net Income (ttm) | 668.07M |
| Shares Out | 166.53M |
| EPS (ttm) | 4.00 |
| PE Ratio | 18.93 |
| Forward PE | 19.53 |
| Dividend | $0.96 (1.26%) |
| Ex-Dividend Date | Jul 30, 2024 |
| Volume | 209,852 |
| Open | 75.37 |
| Previous Close | 75.41 |
| Day's Range | 75.09 - 76.27 |
| 52-Week Range | 61.60 - 77.72 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 81.00 (+6.41%) |
| Earnings Date | Jul 24, 2024 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Full Company ProfileFinancial Performance
In 2023, RDY's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial numbers in INR Financial StatementsAnalyst Forecast
According to one analyst, the rating for RDY stock is "Buy" and the 12-month stock price forecast is $81.0.
News
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Proli...
Dr. Reddy's Q4 & Full Year FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Capsules--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Avastin--Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Dr. Reddy's Q3 & 9M FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.
Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DJSIWorld--Dr. Reddy's has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agen...
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON & HYDERABAD, India & BASEL, Switzerland--(BUSINESS WIRE)--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: ...
India's Dr. Reddy's R&D centre being inspected by US FDA
India's Dr Reddy's on Tuesday said that its research and development centre in Hyderabad is being inspected by the U.S. Food and Drug Administration.
Dr. Reddy's Q2 FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy's Q1 FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2023.
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #BiologicsLicenseApplication--Dr. Reddy's proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA.
Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRL_TC--Dr. Reddy's announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.
Dr. Reddy's Q4 & FY23 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.
Dr. Reddy's: A Profitable, Predictable Margin Expander
The Profitable Predictable Margin Expanders screener on GuruFocus has been a helpful one for me when searching for quality stocks that show solid growth. It does what the name suggests - it sorts thro...
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced the launch of Regadenoson Injection in the U.S. market.
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces the launch of Treprostinil Injection in the U.S.
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu...
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio
HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product por...
Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Bloomberg--Dr. Reddy's Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. R...